Protein tyrosine phosphatase 1B (PTP1B), a key negative regulator of insulin signaling, is considered as a promising and validated therapeutic target for type 2 diabetes mellitus (T2DM) and obesity. Upon careful study, a series of 2-ethoxy-4-(methoxymethyl)benzamide and 2-ethoxy-5-(methoxymethyl)benzamide analogs designed by the “bioisosteric principle” were discovered, wherein their PTP1B inhibitory potency, type of PTP1B inhibition, selectivity and membrane permeability were evaluated. Among them, compound 10m exhibited high inhibitory activity (IC₅₀ = 0.07 μM), significant selectivity (32-fold) over T-cell PTPase (TCPTP) as well as good membrane permeability (P_app = 2.41 × 10⁻⁶ cm/s). Further studies on cell viability and cellular activity revealed that compound 10m could enhance insulin-stimulated glucose uptake with no significant cytotoxicity.

酪氨酸磷酸酶1B（PTP1B）是胰岛素信号的关键负调节剂，被认为是2型糖尿病（T2DM）和肥胖症的有希望且经过验证的治疗靶标。经过仔细研究，发现了一系列根据“生物立体异构原理”设计的2-乙氧基-4-（甲氧基甲基）苯甲酰胺和2-乙氧基-5-（甲氧基甲基）苯甲酰胺类似物，其中它们对PTP1B的抑制力，对PTP1B抑制的类型，评价了选择性和膜渗透性。其中，化合物10m表现出高抑制活性（IC ₅₀  = 0.07μM），对T细胞PTPase（TCPTP）的选择性（32倍）和良好的膜渗透性（P _app  = 2.41×10 ^-6 厘米/秒）。对细胞活力和细胞活性的进一步研究表明，化合物10m可以增强胰岛素刺激的葡萄糖摄取，而没有明显的细胞毒性。